The Cytotoxic Effect and the Multidrug Resistance Reversing Action of Lignans from Phyllanthus amarus

Abstract

Multidrug resistance (MDR) constitutes the major obstacle to the successful treatment of cancer. In several cancer cells, MDR is thought to be mediated by the super-expression of P-glycoprotein (Pgp). Pgp extrudes drugs from the cells, therefore reducing their cytotoxicity, and its activity inhibition may reverse the MDR phenotype. The present study evaluated the possible cytotoxic effect and MDR reversing properties of the extract and compounds isolated from Phyllanthus amarus. To this purpose, two human leukaemia cell lines were employed: K-562 and its vincristine-resistant counterpart Lucena-1, a Pgp-overexpressing subline. We report here that Lucena-1 was significantly more resistant to the cytotoxicity of P. amarus derivatives: the hexane extract (HE, 100 μg/mL), the lignans-rich fraction (LRF, 100 μg/mL) and the lignans nirtetralin (NIRT, 43.2 μg/mL), niranthin (NIRA, 43 μg/mL) or phyllanthin (PHYLLA, 43 μg/mL) exerted cytotoxic effects on K-562 cells with 40.3, 66.0, 62.0, 61.0 or 24.1 % of cell death, respectively. The cellular toxicity observed on Lucena-1 was 16.3, 40.4, 29.4, 30.2, or 24.8 %, respectively. However, cell treatment with the lignan phyltetralin (PHYLT) up to 41.6 μg/mL had no cytotoxic action on either of the cell lines. P. amarus derivatives were also found to be effective in inhibiting Pgp activity as assessed by rhodamine accumulation in Lucena-1 cells, as were the classical Pgp inhibitors, cyclosporine A (160 nM), PSC-833 (2 μM) and verapamil (5 μM). The lignan NIRT produced the most potent inhibition (EC₅₀ = 29.4 μg/mL) followed by NIRA (44.3 μg/mL), LRF (49.1 μg/mL), PHYLT (99.4 μg/mL), PHYLLA and HE (> 100 μg/mL). Lucena-1 cells were more resistant to daunorubicin-induced cell death (LC₅₀ = 50 μM) than K562 cells (LC₅₀ = 4.95 μM). Of note, the P. amarus derivatives significantly potentiated 5μM daunorubicin-induced cell death in Lucena-1 cells (P < 0.01) but not in K562 cells. After treatment only with P. amarus derivatives (100 μg/mL HE, 30 μg/mL LRF, 12.9 μg/mL NIRA, 43.2 μg/mL NIRT, 43 μg/mL PHYLLA or 41.6 μg/mL PHYLT), the Lucena-1 cellular viability was 83.7, 85.3, 101, 69.7, 75.6 or 88.7 %, respectively, whereas the in the presence of daunorubincin, which was not cytotoxic per se, the cell viability decreased to 42.9, 42.2, 64.2, 35.4, 30.4 or 52.6 %, respectively. Together, these results suggest a potential action of P. amarus derivatives as MDR reversing agents, mainly due to their ability to synergize with the action of conventional chemotherapeutics.

Key words

Phyllanthus amarus - Euphorbiaceae - lignans - multidrug resistance - P-glycoprotein - human leukaemia cells - cancer

References

• 1 Biedler J L, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies.  Cancer Res. 1970;  30 1174-84
• 2 Juliano R L, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.  Biochim Biophys Acta. 1976;  455 152-62
• 3 Ambudkar S V, Kimchi-Sarfaty C, Sauna Z E, Gottesman M M. P-glycoprotein: from genomics to mechanism.  Oncogene. 2003;  22 7468-85
• 4 Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.  Cancer Res. 1989;  49 5002-6
• 5 Ganapathi R, Kuo T, Teeter L, Grabowski D, Ford J. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.  Mol Pharmacol. 1991;  39 1-8
• 6 Hait W N, Stein J M, Koletsky A J, Harding M W, Handschumacher R E. Activity of cyclosporin A and a non-immunosuppressive cyclosporin against multidrug resistant leukemic cell lines.  Cancer Commun. 1989;  1 35-43
• 7 Twentyman P R, Bleehen N M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected].  Eur J Cancer. 1991;  27 1639-42
• 8 Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar S V, Limtrakul P. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder.  Biochem Pharmacol. 2004;  68 2043-52
• 9 Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract.  Cancer Chemother Pharmacol. 2004;  54 525-30
• 10 Somanabandhu A, Nitayangkura S, Mahidol C, Ruchirawat S, Likhitwitayawuid K, Shieh H L. et al . 1H- and 13C-nmr assignments of phyllanthin and hypophyllanthin: lignans that enhance cytotoxic responses with cultured multidrug-resistant cells.  J Nat Prod. 1993;  56 233-9
• 11 Chang W L, Chiu L W, Lai J H, Lin H C. Immunosuppressive flavones and lignans from Bupleurum scorzonerifolium .  Phytochemistry. 2003;  64 1375-9
• 12 Tibirica E. Cardiovascular properties of yangambin, a lignan isolated from Brazilian plants.  Cardiovasc Drug Rev. 2001;  19 313-28
• 13 Pullela S V, Takamatsu S, Khan S I, Khan I A. Isolation of lignans and biological activity studies of Ephedra viridis .  Planta Med. 2005;  71 789-91
• 14 Wang C Y, Sun S W, Lee S S. Pharmacokinetic and metabolic studies of retrojusticidin B, a potential anti-viral lignan, in rats.  Planta Med. 2004;  70 1161-5
• 15 Kassuya C A, Leite D F, de Melo L V, Rehder V L, Calixto J B. Anti-inflammatory properties of extracts, fractions and lignans isolated from Phyllanthus amarus .  Planta Med. 2005;  71 721-6
• 16 Chen Y G, Wu Z C, Gui S H, Lv Y P, Liao X R, Halaweish F. Lignans from Schisandra hernyi with DNA cleaving activity and cytotoxic effect on leukemia and Hela cells in vitro .  Fitoterapia. 2005;  76 370-3
• 17 Calixto J B, Santos A R, Cechinel Filho V, Yunes R A. A review of the plants of the genus Phyllanthus: their chemistry, pharmacology, and therapeutic potential.  Med Res Rev. 1998;  18 225-58
• 18 Rajeshkumar N V, Kuttan R. Phyllanthus amarus extract administration increases the life span of rats with hepatocellular carcinoma.  J Ethnopharmacol. 2000;  73 215-9
• 19 Rajeshkumar N V, Joy K L, Kuttan G, Ramsewak R S, Nair M G, Kuttan R. Antitumour and anticarcinogenic activity of Phyllanthus amarus extract.  J Ethnopharmacol. 2002;  81 17-22
• 20 Kassuya C A, Silvestre A A, Rehder V L, Calixto J B. Anti-allodynic and anti-oedematogenic properties of the extract and lignans from Phyllanthus amarus in models of persistent inflammatory and neuropathic pain.  Eur J Pharmacol. 2003;  478 145-53
• 21 Rumjanek V M, Trindade G S, Wagner-Souza K, de-Oliveira M C, Marques-Santos L F, Maia R C. et al . Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1.  An Acad Bras Cienc. 2001;  73 57-69
• 22 Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.  J Immunol Methods. 1983;  65 55-63
• 23 Neyfakh A A. Use of fluorescent dyes as molecular probes for the study of multidrug resistance.  Exp Cell Res. 1988;  174 168-76
• 24 Song S, Suzuki H, Terasaki T, Lemaire M, Sugiyama Y. Modulation of the tumor disposition of vinca alkaloids by PSC 833 in vitro and in vivo .  J Pharmacol Exp Ther. 1998;  287 963-8
• 25 Lozzio B B, Lozzio C B. Properties of the K562 cell line derived from a patient with chronic myeloid leukemia.  Int J Cancer. 1977;  19 136
• 26 Gordaliza M, Garcia P A, del Corral J M, Castro M A, Gomez-Zurita M A. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives.  Toxicon. 2004;  44 441-59
• 27 Fernandes J, Castilho R O, da Costa M R, Wagner-Souza K, Coelho Kaplan M A, Gattass C R. Pentacyclic triterpenes from Chrysobalanaceae species: cytotoxicity on multidrug resistant and sensitive leukemia cell lines.  Cancer Lett. 2003;  190 165-9
• 28 Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M. et al . P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.  Leukemia. 2004;  18 401-8
• 29 Coley H M, Twentyman P R, Workman P. The efflux of anthracyclines in multidrug-resistant cell lines.  Biochem Pharmacol. 1993;  46 1317-26
• 30 Maia R C, Silva E A, Harab R C, Lucena M, Pires V, Rumjanek V M. Sensitivity of vincristine-sensitive K562 and vincristine-resistant K562-Lucena 1 cells to anthracyclines and reversal of multidrug resistance.  Braz J Med Biol Res. 1996;  29 467-72
• 31 Ford J M, Hait W N. Pharmacology of drugs that alter multidrug resistance in cancer.  Pharmacol Rev. 1990;  42 155-99